{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T04:50:45Z","timestamp":1773204645486,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.peptides.2015.03.024","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T19:21:55Z","timestamp":1428261715000},"page":"47-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats"],"prefix":"10.1016","volume":"69","author":[{"given":"Jolanta","family":"Skarbaliene","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Secher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Jelsing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Ansarullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trine S.R.","family":"Neerup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Billestrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keld","family":"Fosgerau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2015.03.024_bib0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)60679-X","article-title":"National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants","author":"Danaei","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2015.03.024_bib0210","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cmet.2010.04.009","article-title":"The stunned beta cell: a brief history","author":"Ferrannini","year":"2010","journal-title":"Cell Metab"},{"key":"10.1016\/j.peptides.2015.03.024_bib0215","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","article-title":"U.K. Prospective Diabetes Study 16. Overview of 6 years\u2019 therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group","author":"United Kingdom Prospective Diabetes Study (UKPDS) Group","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2015.03.024_bib0220","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2337\/dc09-1914","article-title":"DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks","author":"Buse","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2015.03.024_bib0225","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1463-1326.2010.01356.x","article-title":"Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes","author":"Garber","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.peptides.2015.03.024_bib0230","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1432-2277.2009.00984.x","article-title":"Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture","author":"Toso","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.peptides.2015.03.024_bib0235","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1210\/en.2002-220405","article-title":"Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats","author":"Farilla","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2015.03.024_bib0240","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1254\/jphs.09178FP","article-title":"Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats","author":"Kwon","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.peptides.2015.03.024_bib0245","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","article-title":"Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats","author":"Xu","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2015.03.024_bib0250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","author":"Finan","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.peptides.2015.03.024_bib0255","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1463-1326.2012.01676.x","article-title":"The novel GLP-1-gastrin dual agonist, ZP3022, increases beta-cell mass and prevents diabetes in db\/db mice","author":"Fosgerau","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.peptides.2015.03.024_bib0260","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1152\/physrev.00014.2005","article-title":"Cholecystokinin and gastrin receptors","author":"Dufresne","year":"2006","journal-title":"Physiol Rev"},{"key":"10.1016\/j.peptides.2015.03.024_bib0265","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3122\/jabfm.2012.01.100161","article-title":"Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes","author":"Crouch","year":"2012","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.peptides.2015.03.024_bib0270","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1016\/j.diabres.2010.09.007","article-title":"Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients \u2013 a retrospective analysis","author":"Hove","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.peptides.2015.03.024_bib0275","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1016\/S0021-9258(18)60721-5","article-title":"Differential gastrin gene expression in rat gastrointestinal tract and pancreas during neonatal development","author":"Brand","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1016\/j.peptides.2015.03.024_bib0280","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000014111","article-title":"Hormonal control of rat fetal pancreas development","author":"Morisset","year":"1999","journal-title":"Biol Neonate"},{"key":"10.1016\/j.peptides.2015.03.024_bib0285","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2337\/diabetes.51.3.686","article-title":"Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue","author":"Rooman","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2015.03.024_bib0290","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.2337\/db08-0688","article-title":"Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice","author":"Suarez-Pinzon","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2015.03.024_bib0295","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3727\/096368908786092775","article-title":"Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice","author":"Suarez-Pinzon","year":"2008","journal-title":"Cell Transplant"},{"key":"10.1016\/j.peptides.2015.03.024_bib0300","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3727\/096368910X557263","article-title":"Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces beta-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice","author":"Suarez-Pinzon","year":"2011","journal-title":"Cell Transplant"},{"key":"10.1016\/j.peptides.2015.03.024_bib0305","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/jpet.114.215293","article-title":"The novel GLP-1-gastrin dual agonist, ZP3022, improves glucose homeostasis and increases beta cell mass without affecting islet number in db\/db mice","author":"Dalboge","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.peptides.2015.03.024_bib0310","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1463-1326.2009.01049.x","article-title":"Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARalpha\/gamma agonist on glycaemic control in Zucker diabetic fatty rats","author":"Brand","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.peptides.2015.03.024_bib0315","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1152\/ajpendo.00182.2012","article-title":"The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis","author":"Vrang","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.peptides.2015.03.024_bib0320","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1463-1326.2008.00865.x","article-title":"Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats","author":"Larsen","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.peptides.2015.03.024_bib0325","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.bjp.0705397","article-title":"GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics","author":"Sturis","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.peptides.2015.03.024_bib0330","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.2040-1124.2010.00044.x","article-title":"Combination treatment of db\/db mice with exendin-4 and gastrin preserves b-cell mass by stimulating b-cell growth and differentiation","author":"Tamaki","year":"2010","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.peptides.2015.03.024_bib0335","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1210\/en.2011-0066","article-title":"Gastrin treatment stimulates beta-cell regeneration and improves glucose tolerance in 95% pancreatectomized rats","author":"Tellez","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2015.03.024_bib0340","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2337\/diabetes.47.3.358","article-title":"Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat","author":"Pick","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2015.03.024_bib0345","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/00365528109181994","article-title":"Acid secretory potency and elimination of the 15-leucine gastrin-17 analogue in man","author":"Petersen","year":"1981","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.peptides.2015.03.024_bib0350","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1124\/mol.110.065664","article-title":"Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening","author":"Koole","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.peptides.2015.03.024_bib0355","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/db09-0278","article-title":"Glucagon-like peptide 1\/glucagon receptor dual agonism reverses obesity in mice","author":"Pocai","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2015.03.024_bib0360","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/gast.2001.27998","article-title":"Mitogenic effect of gastrin and expression of gastrin receptors in duct-like cells of rat pancreas","author":"Rooman","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.peptides.2015.03.024_bib0365","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1177\/002215540305101110","article-title":"Localization of cholecystokinin receptor subtypes in the endocine pancreas","author":"Morisset","year":"2003","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.peptides.2015.03.024_bib0370","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2337\/diabetes.52.1.124","article-title":"Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor","author":"Buteau","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2015.03.024_bib0375","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0016-5085(99)70231-3","article-title":"Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor","author":"Miyazaki","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.peptides.2015.03.024_bib0380","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1210\/jc.2004-0761","article-title":"Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an increase in functional {beta}-cell mass","author":"Suarez-Pinzon","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.peptides.2015.03.024_bib0385","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.2337\/diabetes.54.9.2596","article-title":"Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice","author":"Suarez-Pinzon","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2015.03.024_bib0390","doi-asserted-by":"crossref","first-page":"E745","DOI":"10.1152\/ajpendo.00030.2002","article-title":"The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice","author":"Rolin","year":"2002","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.peptides.2015.03.024_bib0395","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1210\/en.2006-1064","article-title":"Involvement of cholecystokinin 2 receptor in food intake regulation: hyperphagia and increased fat deposition in cholecystokinin 2 receptor-deficient mice","author":"Clerc","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2015.03.024_bib0400","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4158\/EP12138.RA","article-title":"Distinctions between the islets of mice and men: implications for new therapies for type 1 and 2 diabetes","author":"Levetan","year":"2013","journal-title":"Endocr Pract"}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978115000911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978115000911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T06:46:25Z","timestamp":1651646785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978115000911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":40,"alternative-id":["S0196978115000911"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2015.03.024","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2015.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}